Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ингибиторы протонной помпы и болезни печени: современное состояние вопроса
Ингибиторы протонной помпы и болезни печени: современное состояние вопроса
М.Ф.Осипенко, Е.АЖук. Ингибиторы протонной помпы и болезни печени: современное состояние вопроса. Consilium Medicum. Гастроэнтерология (Прил.). 2013; 1: 18-20.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Jung SW, Lee SW, Hyun JJ et al. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis 2009; 41 (2): 134-40.
2. Lodato F, Azzaroli F, Di Girolamo M et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol 2008; 14 (19): 2980–5.
3. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101 (9): 2128–38.
4. Пасечников В.Д. Ключи к выбору оптимального ингибитора протонной помпы для терапии кислотозависимых заболеваний. РЖГГК. 2004; 3: 32–9.
5. Furuta T, Shirai N, Sugimoto M et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20 (3): 153–67.
6. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19 (12): 911–27.
7. Chao K, Bridgewater FH, Maddern GJ. Acute upper gastrointestinal haemorrhage resulting in transient hepatic failure following liver resection. HPB (Oxford). 2005; 7 (4): 316–7.
8. Johnson EA, Spier BJ, Leff JA et al. Optimising the care of patients with cirrhosis and gastrointestinal haemorrhage: a quality improvement study. Aliment Pharmacol Ther 2011; 34 (1): 76–82.
9. Mitrică D, Pleşa A, Constantinescu R et al. Efficacy of Helicobacter pylori eradication therapy in cirrhotic patients with peptic ulcer disease. Rev Med Chir Soc Med Nat Iasi 2011; 115 (2): 367–74.
10. Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol 2010; 16 (46): 5869–73.
11. van Vlerken LG, Huisman EJ, van Hoek B et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest 2012; 42 (7): 760–7.
12. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta-analysis. Int J Clin Pract 2011; 65 (6): 674–8.
13. Bajaj JS, Ananthakrishnan AN, Hafeezullah M et al.. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol 2010; 105 (1): 106–13.
14. Jamil S, Ahmed S, Memon A et al. Factors predicting the recurrence of spontaneous bacterial peritonitis in patients with cirrhosis. J Coll Physicians Surg Pak 2011; 21 (7): 407–10.
15. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51 (3): 460–82.
16. Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol 2010; 3: 11–6.
17. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36 (1): 37–47.
2. Lodato F, Azzaroli F, Di Girolamo M et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol 2008; 14 (19): 2980–5.
3. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101 (9): 2128–38.
4. Пасечников В.Д. Ключи к выбору оптимального ингибитора протонной помпы для терапии кислотозависимых заболеваний. РЖГГК. 2004; 3: 32–9.
5. Furuta T, Shirai N, Sugimoto M et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20 (3): 153–67.
6. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19 (12): 911–27.
7. Chao K, Bridgewater FH, Maddern GJ. Acute upper gastrointestinal haemorrhage resulting in transient hepatic failure following liver resection. HPB (Oxford). 2005; 7 (4): 316–7.
8. Johnson EA, Spier BJ, Leff JA et al. Optimising the care of patients with cirrhosis and gastrointestinal haemorrhage: a quality improvement study. Aliment Pharmacol Ther 2011; 34 (1): 76–82.
9. Mitrică D, Pleşa A, Constantinescu R et al. Efficacy of Helicobacter pylori eradication therapy in cirrhotic patients with peptic ulcer disease. Rev Med Chir Soc Med Nat Iasi 2011; 115 (2): 367–74.
10. Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol 2010; 16 (46): 5869–73.
11. van Vlerken LG, Huisman EJ, van Hoek B et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest 2012; 42 (7): 760–7.
12. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta-analysis. Int J Clin Pract 2011; 65 (6): 674–8.
13. Bajaj JS, Ananthakrishnan AN, Hafeezullah M et al.. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol 2010; 105 (1): 106–13.
14. Jamil S, Ahmed S, Memon A et al. Factors predicting the recurrence of spontaneous bacterial peritonitis in patients with cirrhosis. J Coll Physicians Surg Pak 2011; 21 (7): 407–10.
15. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51 (3): 460–82.
16. Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol 2010; 3: 11–6.
17. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36 (1): 37–47.
Авторы
М.Ф.Осипенко, Е.АЖук
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава РФ
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.